Shi Wenbao, Luo Jing, Yang Liu, Chen Dalin, Zhang Yongqin, Peng Jun, Ruetzler Kurt, Sun Manyun, Jin Hua
Department of Anesthesiology, Affiliated Hospital of Kunming University of Science and Technology, the First People's Hospital of Yunnan Province, Kunming, China.
Department of Anesthesiology, Gejiu People's Hospital, Gejiu, China.
J Thorac Dis. 2025 Jun 30;17(6):4091-4103. doi: 10.21037/jtd-2025-827. Epub 2025 Jun 25.
Body mass index (BMI) has a complex association with a variety of chronic pain conditions, which may be influenced by sleep apnea syndrome (SAS). However, the role of SAS within the causal pathway linking BMI to chronic pain remains unconfirmed. This study explored whether and to what extent SAS serves as a mediator between BMI and chronic pain using Bayesian-weighted Mendelian randomization (BWMR) techniques.
This study utilized genome-wide association study (GWAS) summary data for BMI (N=461,460) and SAS (N=476,853; based on ICD-10 code diagnostic registries) from the IEU OpenGWAS database, along with chronic pain GWAS data (ICD-10 code-based diagnostic registries) from the FinnGen database. Utilizing BWMR and inverse-variance weighted (IVW) methods, a two-step, two-sample Mendelian randomization (MR) design was employed to investigate the causal relationships between BMI and various types of chronic pain and to assess the mediating role of SAS in the BMI-chronic pain link. Additionally, a suite of sensitivity analyses, including the use of MR-PRESSO to remove outliers, MR-Egger regression to assess horizontal pleiotropy, and Cochran's Q test to evaluate heterogeneity, thereby ensuring the robustness and reliability of the MR study findings.
The GWAS data for BMI, SAS, and chronic pain were all derived from European populations, comprising 9,851,867 BMI-associated single-nucleotide polymorphisms (SNPs), 24,183,940 SAS-related SNPs, and 19,680,346 to 19,682,705 chronic pain-linked SNPs in the respective datasets. BWMR revealed significant genetic associations between BMI and various types of chronic pain, including limb pain [odds ratio (OR) =1.34, 95% confidence interval (CI): 1.25-1.44, P<0.001], low back pain (OR =1.34, 95% CI: 1.25-1.43, P<0.001), low back pain with or without sciatica (OR =1.28, 95% CI: 1.21-1.36, P<0.001), and thoracic spine pain (OR =1.18, 95% CI: 1.03-1.36, P=0.02). Additionally, the genetic predisposition of BMI was also strongly associated with the risk of SAS (OR =2.34, 95% CI: 2.12-2.59, P<0.001). Mediation analysis revealed that SAS mediated 15.3% (β=0.045) of BMI's causal effect on limb pain, 26.8% (β=0.078) on low back pain, and 26.8% (β=0.067) on low back pain with or without sciatica.
There is a causal relationship between BMI and chronic pain, with SAS acting as a mediator for a portion of the causal effects of BMI on conditions such as limb pain, low back pain, and low back pain with or without sciatica. Therefore, clinical strategies should focus on modulating BMI levels to maintain them within the normal range, which may effectively reduce the incidence risk of chronic pain. Furthermore, in patients with elevated BMI and comorbid SAS, targeted SAS treatment could potentially mitigate BMI-associated chronic pain burden.
体重指数(BMI)与多种慢性疼痛状况存在复杂关联,这可能受睡眠呼吸暂停综合征(SAS)影响。然而,SAS在将BMI与慢性疼痛联系起来的因果路径中的作用仍未得到证实。本研究使用贝叶斯加权孟德尔随机化(BWMR)技术探讨了SAS是否以及在多大程度上作为BMI与慢性疼痛之间的中介。
本研究利用了来自IEU OpenGWAS数据库的BMI(N = 461,460)和SAS(N = 476,853;基于国际疾病分类第十版(ICD - 10)编码诊断登记)的全基因组关联研究(GWAS)汇总数据,以及来自芬兰基因数据库的慢性疼痛GWAS数据(基于ICD - 10编码的诊断登记)。利用BWMR和逆方差加权(IVW)方法,采用两步两样本孟德尔随机化(MR)设计来研究BMI与各种类型慢性疼痛之间的因果关系,并评估SAS在BMI - 慢性疼痛关联中的中介作用。此外,还进行了一系列敏感性分析,包括使用MR - PRESSO去除异常值、MR - Egger回归评估水平多效性以及 Cochr an's Q检验评估异质性,从而确保MR研究结果的稳健性和可靠性。
BMI、SAS和慢性疼痛的GWAS数据均来自欧洲人群,各自的数据集中分别包含9,851,867个与BMI相关的单核苷酸多态性(SNP)、24,183,940个与SAS相关的SNP以及19,680,346至19,682,705个与慢性疼痛相关的SNP。BWMR显示BMI与各种类型的慢性疼痛之间存在显著的遗传关联,包括肢体疼痛[优势比(OR)= 1.34,95%置信区间(CI):1.25 - 1.44,P < 0.001]、腰痛(OR = 1.34,95% CI:1.25 - 1.43,P < 0.001)、伴或不伴坐骨神经痛的腰痛(OR = 1.28,95% CI:1.21 - 1.36,P < 0.001)以及胸椎疼痛(OR = 1.18,95% CI:1.03 - 1.36,P = 0.02)。此外,BMI的遗传易感性也与SAS风险密切相关(OR = 2.34,95% CI:2.12 - 2.59,P < 0.001)。中介分析表明,SAS介导了BMI对肢体疼痛因果效应的15.3%(β = 0.045)、对腰痛因果效应的26.8%(β = 0.078)以及对伴或不伴坐骨神经痛的腰痛因果效应的26.8%(β = 0.067)。
BMI与慢性疼痛之间存在因果关系,SAS作为BMI对肢体疼痛、腰痛以及伴或不伴坐骨神经痛的腰痛等状况部分因果效应的中介。因此,临床策略应侧重于调节BMI水平使其保持在正常范围内,这可能有效降低慢性疼痛的发病风险。此外,对于BMI升高且合并SAS的患者,针对性的SAS治疗可能减轻与BMI相关的慢性疼痛负担。